Cargando…
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061446/ https://www.ncbi.nlm.nih.gov/pubmed/37007548 http://dx.doi.org/10.21037/atm-22-6266 |
| _version_ | 1785017293626933248 |
|---|---|
| author | Nardin, Simone Del Mastro, Lucia |
| author_facet | Nardin, Simone Del Mastro, Lucia |
| author_sort | Nardin, Simone |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10061446 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100614462023-03-31 Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer Nardin, Simone Del Mastro, Lucia Ann Transl Med Editorial Commentary AME Publishing Company 2023-01-09 2023-03-15 /pmc/articles/PMC10061446/ /pubmed/37007548 http://dx.doi.org/10.21037/atm-22-6266 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Nardin, Simone Del Mastro, Lucia Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title | Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title_full | Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title_fullStr | Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title_full_unstemmed | Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title_short | Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer |
| title_sort | sacituzumab govitecan in hr-positive her2-negative metastatic breast cancer |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061446/ https://www.ncbi.nlm.nih.gov/pubmed/37007548 http://dx.doi.org/10.21037/atm-22-6266 |
| work_keys_str_mv | AT nardinsimone sacituzumabgovitecaninhrpositiveher2negativemetastaticbreastcancer AT delmastrolucia sacituzumabgovitecaninhrpositiveher2negativemetastaticbreastcancer |